FULC Stock Summary and Trading Ideas (Fulcrum Therapeutics | NASDAQ:FULC)

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Fulcrum Therapeutics trades on the NASDAQ stock market under the symbol FULC.

As of March 6, 2026, FULC stock price climbed to $8.17 with 739,973 million shares trading.

FULC has a beta of 1.85, meaning it tends to be more sensitive to market movements. FULC has a correlation of 0.11 to the broad based SPY ETF.

FULC has a market cap of $544.12 million. This is considered a Small Cap stock.

In the last 3 years, FULC traded as high as $15.74 and as low as $2.25.

The top ETF exchange traded funds that FULC belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

FULC has outperformed the market in the last year with a return of +151.4%, while the SPY ETF gained +16.6%. However, in the most recent history, FULC shares have underperformed the stock market with its stock returning -8.2% in the last 3 month period and -30.3% for the last 2 week period, while SPY has returned -1.7% and -1.8%, respectively.

FULC support price is $7.79 and resistance is $8.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FULC shares will trade within this expected range on the day.